Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe-Reference-Cited by-同舟云学术

Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe

Published:2024-05 Issue:10 Volume:13 Page:
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Aydilek Enver¹^ORCID,Wulf Gerald¹,Schwarz Friedrich¹²^ORCID,Bacher Ulrike³^ORCID,Rummel Mathias⁴,Stiefel Olga⁵,Kerkhoff Andrea⁶,Maulhardt Markus¹,Melchardt Thomas⁷,Pabst Thomas⁸,Lenz Georg⁶,Shumilov Evgenii⁶

Affiliation:

1. Department for Hematology and Medical Oncology University Medical Center Göttingen Göttingen Germany

2. Campus Institute for Dynamics of Biological Networks, Georg August University Göttingen Germany

3. Department of Hematology, Inselspital University Hospital Bern, University of Bern Bern Switzerland

4. Department of Hematology, Clinic for Haematology and Medical Oncology Justus Liebig University Hospital Gießen Germany

5. Division of Hematology With Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I Ordensklinikum Linz Linz Austria

6. Department of Medicine A, Hematology, Oncology and Pneumology University Hospital Muenster Muenster Germany

7. Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology Paracelsus Medical University Salzburg Austria

8. Department of Medical Oncology Inselspital Bern University Hospital Bern Switzerland

Abstract

AbstractBackgroundMantle cell lymphoma (MCL) is a type of B‐cell lymphoma that is currently incurable. Pirtobrutinib shows promising response rates in heavily pretreated MCL patients according to the approval study, but the real‐world data are scarce.MethodsIn this study, we retrospectively analyzed the efficacy and safety profile of pirtobrutinib in 10 relapsed/refractory MCL patients from compassionate use program (CUP).ResultsOn average, the patients underwent three lines of systemic therapy prior to pirtobrutinib and were predominantly BTKi exposed (9/10). The best overall response rate (BORR) was 67%. In a median follow‐up of 8.6 months, the mean duration of response (DOR), progression‐free survival (PFS), and overall survival (OS) were not reached. No new safety signals were documented.ConclusionsIn summary, pirtobrutinib represented a safe and effective treatment option in a small real‐world population.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.7289

Reference16 articles.

1. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

2. The B cell receptor signaling pathway in mantle cell lymphoma

3. Role of Bruton’s tyrosine kinase in B cells and malignancies

4. Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network